We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
LGHLW | Lion Group Holding Ltd | 0.0087 | 0.0034 | 64.15% | 6,080,925 |
KXIN | Kaixin Holdings | 0.21 | 0.0712 | 51.30% | 15,668,360 |
KITT | Nauticus Robotics Inc | 0.3429 | 0.112 | 48.51% | 71,418,924 |
BWAQ | Blue World Acquisition Corporation | 9.14 | 2.32 | 34.02% | 556,916 |
PIXY | ShiftPixy Inc | 1.90 | 0.44 | 30.14% | 6,734,421 |
CITE | Cartica Acquisition Corporation | 14.25 | 3.03 | 27.01% | 2,286 |
CHR | Cheer Holding Inc | 3.26 | 0.67 | 25.87% | 26 |
WAVD | WaveDancer Inc | 2.80 | 0.53 | 23.35% | 5 |
CYN | CYNGN Inc | 0.1222 | 0.0229 | 23.06% | 18,933,030 |
QSG | QuantaSing Group Ltd | 1.97 | 0.34 | 20.86% | 4,218,034 |
CMND | Clearmind Medicine Inc | 1.23 | 0.21 | 20.59% | 2,184,039 |
THE WOODLANDS, Texas, June 10, 2024 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today received notice that the U.S. government intends to terminate the existing South Texas Family Residential Center ("STFRC") services agreement with Target's migrant programming partner ("STFRC Partner"), effective in 60 days, or on or about August 9, 2024 ("Effective Date").
Knightscope, Inc. [Nasdaq: KSCP] (“Knightscope” or the “Company”), an innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, today announces a new contract from an Ivy League school for a custom K1 Blue Light Tower. This purchase is part of the university’s initial evaluation that is expected to lead to a larger rollout across campus in the near future.
The deployment will help Valeo develop the technologies needed to make the car more electrified, autonomous and software driven. It will also support the optimization of the company’s research and development expenses.
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 66,982.32 | -2,526.17 | -3.63% | 1.32T | 4,258,979,310 |
ETH | Ethereum | 3,531.57 | -134.18 | -3.66% | 425.15B | 2,299,956,938 |
USDT | Tether USD | 0.999 | -0.00052 | -0.05% | 97.74B | 213,113,653 |
BNB | Binance Coin | 609.06 | -15.89 | -2.54% | 95.94B | 549,663,619 |
SOL | Solana | 153.75 | -5.24 | -3.30% | 67.97B | 671,319,484 |
STETH | stETH | 3,528.32 | -120.68 | -3.31% | 34.68B | 7,645,681 |
USDC | USD Coin | 0.9999 | 0.00 | 0.00% | 28.07B | 862,984,470 |
XRP | Ripple | 0.4831 | -0.0136 | -2.74% | 26.42B | 271,113,245 |
TONCOIN | Wrapped TON Coin | 6.83 | -0.365731 | -5.08% | 23.75B | 91,913,751 |
DOGE | Dogecoin | 0.14077 | -0.0039 | -2.70% | 20.24B | 235,371,605 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions